Additionally, high-throughput screening was essential to Rao et al. when screening 169 epigenetic compounds using TNBC PDOs, ultimately determining the anti-tumor activity of panobinostat (targeting histone deacetylase), pacritinib (targeting JAK/STAT), TAK-901 (targeting histone demethylases), and JIB-04 (targeting aurora kinase pathways) [88]. The gene discussed is CDK9; the disease is neoplasm.